Concepts (244)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Placenta Accreta | 18 | 2025 | 155 | 12.290 |
Why?
|
| Hysterectomy | 15 | 2025 | 192 | 5.870 |
Why?
|
| Cesarean Section | 14 | 2025 | 387 | 4.910 |
Why?
|
| Pregnancy | 34 | 2025 | 7167 | 2.200 |
Why?
|
| Perinatal Death | 3 | 2023 | 26 | 1.900 |
Why?
|
| Dacarbazine | 3 | 2015 | 86 | 1.400 |
Why?
|
| Postpartum Hemorrhage | 4 | 2025 | 96 | 1.390 |
Why?
|
| Fetal Diseases | 4 | 2024 | 447 | 1.340 |
Why?
|
| Placenta | 8 | 2023 | 506 | 1.200 |
Why?
|
| Retrospective Studies | 23 | 2025 | 16231 | 1.120 |
Why?
|
| Blood Loss, Surgical | 2 | 2025 | 152 | 1.120 |
Why?
|
| Oligohydramnios | 2 | 2025 | 46 | 1.090 |
Why?
|
| Uterine Hemorrhage | 2 | 2024 | 43 | 1.090 |
Why?
|
| Antineoplastic Agents, Alkylating | 3 | 2015 | 98 | 1.030 |
Why?
|
| Fetofetal Transfusion | 3 | 2025 | 192 | 0.990 |
Why?
|
| Watchful Waiting | 2 | 2025 | 68 | 0.960 |
Why?
|
| Conservative Treatment | 1 | 2025 | 33 | 0.950 |
Why?
|
| Case-Control Studies | 8 | 2025 | 3268 | 0.950 |
Why?
|
| Balloon Occlusion | 1 | 2025 | 47 | 0.940 |
Why?
|
| Placenta Previa | 2 | 2022 | 65 | 0.940 |
Why?
|
| Female | 39 | 2025 | 66303 | 0.930 |
Why?
|
| Blood Transfusion | 5 | 2025 | 308 | 0.920 |
Why?
|
| Blood Transfusion, Intrauterine | 1 | 2024 | 37 | 0.920 |
Why?
|
| Amniotic Fluid | 3 | 2025 | 151 | 0.880 |
Why?
|
| Uterine Artery Embolization | 1 | 2023 | 4 | 0.850 |
Why?
|
| Urinary Tract | 1 | 2023 | 60 | 0.850 |
Why?
|
| Infant, Newborn | 14 | 2025 | 8184 | 0.840 |
Why?
|
| Fetoscopy | 2 | 2025 | 439 | 0.840 |
Why?
|
| Tranexamic Acid | 1 | 2023 | 19 | 0.830 |
Why?
|
| Laser Coagulation | 1 | 2024 | 129 | 0.830 |
Why?
|
| Glioblastoma | 3 | 2015 | 334 | 0.820 |
Why?
|
| Pregnancy Outcome | 6 | 2025 | 589 | 0.790 |
Why?
|
| Oncologists | 1 | 2022 | 29 | 0.780 |
Why?
|
| Respiratory Distress Syndrome, Newborn | 1 | 2022 | 79 | 0.780 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2015 | 721 | 0.730 |
Why?
|
| Ultrasonography, Prenatal | 4 | 2025 | 963 | 0.730 |
Why?
|
| Meningomyelocele | 2 | 2025 | 237 | 0.710 |
Why?
|
| Intensive Care Units | 1 | 2024 | 482 | 0.700 |
Why?
|
| Humans | 46 | 2025 | 124401 | 0.690 |
Why?
|
| Goiter | 2 | 2019 | 7 | 0.660 |
Why?
|
| Propylthiouracil | 2 | 2019 | 9 | 0.660 |
Why?
|
| Premature Birth | 2 | 2023 | 384 | 0.660 |
Why?
|
| Thyroxine | 2 | 2019 | 69 | 0.640 |
Why?
|
| Urinary Bladder, Neurogenic | 1 | 2019 | 45 | 0.640 |
Why?
|
| Thyroid Diseases | 1 | 2019 | 33 | 0.620 |
Why?
|
| Spine | 1 | 2019 | 143 | 0.620 |
Why?
|
| Vulvovaginitis | 1 | 2017 | 2 | 0.560 |
Why?
|
| Mental Disorders | 1 | 2024 | 824 | 0.550 |
Why?
|
| Neurosurgical Procedures | 1 | 2019 | 307 | 0.540 |
Why?
|
| Symptom Assessment | 1 | 2017 | 100 | 0.530 |
Why?
|
| Prenatal Injuries | 1 | 2015 | 2 | 0.510 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2025 | 3578 | 0.500 |
Why?
|
| Thyroid Hormones | 1 | 2015 | 67 | 0.490 |
Why?
|
| Prenatal Diagnosis | 5 | 2025 | 597 | 0.480 |
Why?
|
| Adult | 15 | 2025 | 29397 | 0.480 |
Why?
|
| Pregnancy, Twin | 3 | 2025 | 177 | 0.470 |
Why?
|
| Bone Marrow Cells | 2 | 2015 | 261 | 0.470 |
Why?
|
| Hedgehog Proteins | 1 | 2015 | 189 | 0.440 |
Why?
|
| Receptors, Cell Surface | 1 | 2015 | 469 | 0.400 |
Why?
|
| Polycythemia | 2 | 2024 | 43 | 0.400 |
Why?
|
| Insurance Coverage | 2 | 2023 | 121 | 0.390 |
Why?
|
| Anesthesia, General | 2 | 2022 | 118 | 0.360 |
Why?
|
| Neurogenesis | 1 | 2012 | 190 | 0.350 |
Why?
|
| Brain Neoplasms | 2 | 2015 | 1243 | 0.320 |
Why?
|
| MicroRNAs | 1 | 2015 | 840 | 0.290 |
Why?
|
| Hyperthyroidism | 2 | 2019 | 26 | 0.280 |
Why?
|
| Twins, Monozygotic | 2 | 2025 | 117 | 0.280 |
Why?
|
| Treatment Outcome | 4 | 2025 | 12286 | 0.250 |
Why?
|
| Insurance, Health | 2 | 2023 | 137 | 0.250 |
Why?
|
| Polyhydramnios | 1 | 2025 | 56 | 0.230 |
Why?
|
| Neurons | 2 | 2012 | 1966 | 0.230 |
Why?
|
| Rh Isoimmunization | 1 | 2024 | 28 | 0.230 |
Why?
|
| Parvoviridae Infections | 1 | 2024 | 36 | 0.230 |
Why?
|
| Pregnancy Trimester, Second | 1 | 2025 | 166 | 0.230 |
Why?
|
| Operative Time | 1 | 2025 | 166 | 0.230 |
Why?
|
| Transfection | 3 | 2015 | 1069 | 0.220 |
Why?
|
| Sutures | 1 | 2024 | 67 | 0.220 |
Why?
|
| Pleural Effusion | 1 | 2024 | 101 | 0.220 |
Why?
|
| Cell Line, Tumor | 3 | 2015 | 3342 | 0.220 |
Why?
|
| Apgar Score | 1 | 2023 | 47 | 0.220 |
Why?
|
| Uterine Artery | 1 | 2023 | 29 | 0.210 |
Why?
|
| Patient Admission | 1 | 2024 | 185 | 0.210 |
Why?
|
| Phenotype | 1 | 2012 | 4256 | 0.200 |
Why?
|
| Depression, Postpartum | 1 | 2023 | 53 | 0.200 |
Why?
|
| Gestational Age | 3 | 2025 | 1161 | 0.200 |
Why?
|
| Cytomegalovirus Infections | 1 | 2024 | 218 | 0.200 |
Why?
|
| Risk Factors | 4 | 2024 | 10149 | 0.200 |
Why?
|
| Child Development | 1 | 2025 | 266 | 0.200 |
Why?
|
| Patient Protection and Affordable Care Act | 1 | 2023 | 63 | 0.190 |
Why?
|
| Jaundice, Neonatal | 1 | 2021 | 11 | 0.190 |
Why?
|
| Mental Health | 1 | 2024 | 346 | 0.180 |
Why?
|
| Rural Population | 1 | 2023 | 257 | 0.180 |
Why?
|
| Obstetrics | 1 | 2023 | 237 | 0.180 |
Why?
|
| Medicaid | 1 | 2023 | 243 | 0.170 |
Why?
|
| Laser Therapy | 1 | 2023 | 250 | 0.170 |
Why?
|
| Hernias, Diaphragmatic, Congenital | 1 | 2025 | 402 | 0.170 |
Why?
|
| Hypoglycemia | 1 | 2021 | 193 | 0.170 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2024 | 449 | 0.160 |
Why?
|
| Diabetes, Gestational | 1 | 2021 | 112 | 0.160 |
Why?
|
| Neurodevelopmental Disorders | 1 | 2025 | 506 | 0.160 |
Why?
|
| Antithyroid Agents | 1 | 2019 | 4 | 0.160 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 2 | 2011 | 81 | 0.160 |
Why?
|
| Length of Stay | 1 | 2025 | 1308 | 0.160 |
Why?
|
| Consensus | 1 | 2022 | 629 | 0.160 |
Why?
|
| Signal Transduction | 4 | 2015 | 4535 | 0.150 |
Why?
|
| Pregnancy Complications | 2 | 2023 | 507 | 0.150 |
Why?
|
| United States | 3 | 2023 | 10773 | 0.150 |
Why?
|
| Hypothyroidism | 1 | 2019 | 93 | 0.140 |
Why?
|
| Health Services Accessibility | 1 | 2023 | 605 | 0.140 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2015 | 1899 | 0.140 |
Why?
|
| Candidiasis, Vulvovaginal | 1 | 2017 | 3 | 0.140 |
Why?
|
| Trichomonas Vaginitis | 1 | 2017 | 13 | 0.140 |
Why?
|
| Vaginosis, Bacterial | 1 | 2017 | 18 | 0.140 |
Why?
|
| Herpes Genitalis | 1 | 2017 | 11 | 0.140 |
Why?
|
| Lichen Planus | 1 | 2017 | 8 | 0.140 |
Why?
|
| Infant, Premature | 1 | 2022 | 815 | 0.140 |
Why?
|
| Lung | 1 | 2025 | 1483 | 0.140 |
Why?
|
| Neonatal Screening | 1 | 2019 | 184 | 0.140 |
Why?
|
| Pilot Projects | 1 | 2021 | 1404 | 0.130 |
Why?
|
| Bone Marrow Neoplasms | 1 | 2015 | 24 | 0.130 |
Why?
|
| Fluoresceins | 1 | 2015 | 35 | 0.120 |
Why?
|
| Binding, Competitive | 1 | 2015 | 184 | 0.120 |
Why?
|
| Blotting, Western | 2 | 2015 | 1108 | 0.120 |
Why?
|
| Caspase 3 | 1 | 2015 | 134 | 0.120 |
Why?
|
| Patched Receptors | 1 | 2015 | 26 | 0.120 |
Why?
|
| Animals | 7 | 2015 | 34146 | 0.120 |
Why?
|
| Patched-1 Receptor | 1 | 2015 | 33 | 0.120 |
Why?
|
| Cricetinae | 1 | 2015 | 411 | 0.120 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2015 | 1288 | 0.120 |
Why?
|
| Surgical Wound Infection | 1 | 2017 | 265 | 0.120 |
Why?
|
| 3' Untranslated Regions | 1 | 2015 | 165 | 0.110 |
Why?
|
| Cells, Cultured | 4 | 2012 | 3052 | 0.110 |
Why?
|
| Nerve Tissue Proteins | 2 | 2011 | 1114 | 0.110 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2015 | 188 | 0.110 |
Why?
|
| Transcriptional Activation | 1 | 2015 | 483 | 0.110 |
Why?
|
| Neoplastic Stem Cells | 1 | 2015 | 300 | 0.110 |
Why?
|
| Connexin 43 | 1 | 2012 | 30 | 0.100 |
Why?
|
| RNA Interference | 1 | 2015 | 503 | 0.100 |
Why?
|
| Gap Junctions | 1 | 2012 | 38 | 0.100 |
Why?
|
| ErbB Receptors | 1 | 2014 | 284 | 0.100 |
Why?
|
| Chemokine CXCL12 | 1 | 2012 | 32 | 0.100 |
Why?
|
| Reproducibility of Results | 1 | 2019 | 2875 | 0.100 |
Why?
|
| Up-Regulation | 1 | 2015 | 862 | 0.100 |
Why?
|
| Cats | 1 | 2012 | 116 | 0.100 |
Why?
|
| HEK293 Cells | 1 | 2015 | 753 | 0.100 |
Why?
|
| Protein Kinase C | 1 | 2012 | 150 | 0.100 |
Why?
|
| Antigens, Surface | 1 | 2012 | 121 | 0.100 |
Why?
|
| Breast Neoplasms | 2 | 2015 | 2507 | 0.100 |
Why?
|
| Mice, Inbred BALB C | 1 | 2014 | 1006 | 0.100 |
Why?
|
| Fetal Growth Retardation | 2 | 2025 | 240 | 0.100 |
Why?
|
| Tumor Microenvironment | 1 | 2015 | 548 | 0.100 |
Why?
|
| Excitatory Postsynaptic Potentials | 1 | 2012 | 131 | 0.100 |
Why?
|
| Tachykinins | 1 | 2011 | 3 | 0.100 |
Why?
|
| Adipogenesis | 1 | 2012 | 77 | 0.090 |
Why?
|
| Species Specificity | 1 | 2012 | 548 | 0.090 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2015 | 1688 | 0.090 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2014 | 887 | 0.090 |
Why?
|
| Diagnosis, Differential | 1 | 2017 | 1892 | 0.090 |
Why?
|
| Osteogenesis | 1 | 2012 | 155 | 0.090 |
Why?
|
| Neoplasm Proteins | 1 | 2015 | 669 | 0.090 |
Why?
|
| Transcription, Genetic | 1 | 2015 | 1702 | 0.080 |
Why?
|
| Repressor Proteins | 2 | 2011 | 820 | 0.080 |
Why?
|
| Cell Proliferation | 1 | 2015 | 2304 | 0.080 |
Why?
|
| Transplantation Tolerance | 1 | 2008 | 15 | 0.070 |
Why?
|
| Spinal Cord Injuries | 1 | 2011 | 310 | 0.070 |
Why?
|
| Cell Transdifferentiation | 1 | 2008 | 66 | 0.070 |
Why?
|
| Immune Tolerance | 1 | 2008 | 145 | 0.070 |
Why?
|
| Dopamine | 1 | 2008 | 284 | 0.070 |
Why?
|
| Regeneration | 1 | 2008 | 203 | 0.060 |
Why?
|
| Gene Expression Regulation | 2 | 2011 | 2535 | 0.060 |
Why?
|
| Lung Volume Measurements | 1 | 2025 | 75 | 0.060 |
Why?
|
| Tensile Strength | 1 | 2024 | 39 | 0.060 |
Why?
|
| Polyesters | 1 | 2024 | 40 | 0.060 |
Why?
|
| Materials Testing | 1 | 2024 | 73 | 0.060 |
Why?
|
| Organ Size | 1 | 2025 | 432 | 0.060 |
Why?
|
| Hysterotomy | 1 | 2025 | 126 | 0.060 |
Why?
|
| Cell Differentiation | 2 | 2008 | 1930 | 0.060 |
Why?
|
| Parity | 1 | 2023 | 78 | 0.050 |
Why?
|
| Cell Communication | 2 | 2015 | 167 | 0.050 |
Why?
|
| Fetal Death | 1 | 2023 | 112 | 0.050 |
Why?
|
| Hypertension, Pregnancy-Induced | 1 | 2023 | 74 | 0.050 |
Why?
|
| Tertiary Care Centers | 1 | 2023 | 236 | 0.050 |
Why?
|
| Constriction | 1 | 2021 | 50 | 0.050 |
Why?
|
| Umbilical Cord | 1 | 2021 | 56 | 0.050 |
Why?
|
| Bilirubin | 1 | 2021 | 122 | 0.040 |
Why?
|
| Young Adult | 3 | 2023 | 8979 | 0.040 |
Why?
|
| Multivariate Analysis | 1 | 2023 | 1417 | 0.040 |
Why?
|
| DNA-Binding Proteins | 1 | 2008 | 2055 | 0.040 |
Why?
|
| Co-Repressor Proteins | 2 | 2011 | 37 | 0.040 |
Why?
|
| Mice | 2 | 2014 | 17729 | 0.040 |
Why?
|
| Genetic Testing | 1 | 2024 | 1004 | 0.040 |
Why?
|
| Ohio | 1 | 2017 | 86 | 0.040 |
Why?
|
| Mass Screening | 1 | 2023 | 784 | 0.040 |
Why?
|
| Anxiety | 1 | 2023 | 967 | 0.030 |
Why?
|
| Time Factors | 2 | 2021 | 6273 | 0.030 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2015 | 109 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2024 | 4733 | 0.030 |
Why?
|
| Depression | 1 | 2023 | 1248 | 0.030 |
Why?
|
| RNA, Messenger | 2 | 2012 | 2824 | 0.030 |
Why?
|
| Cell Survival | 1 | 2015 | 806 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2021 | 3427 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2023 | 6089 | 0.020 |
Why?
|
| Cellular Microenvironment | 1 | 2011 | 8 | 0.020 |
Why?
|
| Activating Transcription Factors | 1 | 2011 | 4 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-jun | 1 | 2011 | 42 | 0.020 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2011 | 54 | 0.020 |
Why?
|
| Response Elements | 1 | 2011 | 97 | 0.020 |
Why?
|
| Transcription Factor AP-1 | 1 | 2011 | 106 | 0.020 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2011 | 109 | 0.020 |
Why?
|
| Tretinoin | 1 | 2011 | 116 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2011 | 254 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2012 | 510 | 0.020 |
Why?
|
| Genes, Reporter | 1 | 2011 | 383 | 0.020 |
Why?
|
| Inflammation Mediators | 1 | 2011 | 235 | 0.020 |
Why?
|
| Incidence | 1 | 2017 | 3086 | 0.020 |
Why?
|
| Infant | 1 | 2025 | 12479 | 0.020 |
Why?
|
| Zebrafish | 1 | 2011 | 389 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2012 | 1625 | 0.020 |
Why?
|
| Nuclear Receptor Subfamily 4, Group A, Member 2 | 1 | 2008 | 33 | 0.020 |
Why?
|
| Biophysical Phenomena | 1 | 2008 | 39 | 0.020 |
Why?
|
| Tyrosine 3-Monooxygenase | 1 | 2008 | 53 | 0.020 |
Why?
|
| Binding Sites | 1 | 2011 | 1296 | 0.020 |
Why?
|
| Phosphopyruvate Hydratase | 1 | 2008 | 31 | 0.020 |
Why?
|
| Cell Growth Processes | 1 | 2008 | 63 | 0.020 |
Why?
|
| Wound Healing | 1 | 2011 | 458 | 0.020 |
Why?
|
| Sodium Channels | 1 | 2008 | 109 | 0.020 |
Why?
|
| Patch-Clamp Techniques | 1 | 2008 | 280 | 0.020 |
Why?
|
| Adult Stem Cells | 1 | 2008 | 53 | 0.020 |
Why?
|
| Membrane Potentials | 1 | 2008 | 304 | 0.020 |
Why?
|
| Protein Binding | 1 | 2011 | 1749 | 0.020 |
Why?
|
| Pluripotent Stem Cells | 1 | 2008 | 75 | 0.020 |
Why?
|
| Adolescent | 2 | 2017 | 19358 | 0.020 |
Why?
|
| Transduction, Genetic | 1 | 2008 | 290 | 0.020 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2008 | 281 | 0.020 |
Why?
|
| Immunization | 1 | 2008 | 307 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2015 | 1674 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2008 | 670 | 0.020 |
Why?
|
| Models, Biological | 1 | 2011 | 1459 | 0.020 |
Why?
|
| Homeodomain Proteins | 1 | 2008 | 546 | 0.020 |
Why?
|
| Child | 1 | 2023 | 24526 | 0.010 |
Why?
|
| Male | 1 | 2025 | 61027 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2008 | 2608 | 0.010 |
Why?
|
| Middle Aged | 1 | 2017 | 26457 | 0.010 |
Why?
|
| Neoplasms | 1 | 2008 | 2800 | 0.010 |
Why?
|